Targetable modifiers of T cell exclusion in KrasG12D -driven colorectal cancer (P02)

• Subject Area: Hematology, Oncology
• Term: since 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 441891347

To understand the mechanism of immune evasion depending on the oncogene and other factors to overcome the limitations of current immunotherapies we will perform in vivo screens using subcutaneous transplantation of CT26 cells as well as different colonic organoids harbouring colorectal cancer driver mutations. To clarify which oncogenes cause resistance to ICB, we will use organoids with or without oncogenic KrasG12D or intact p53 and then study responses. Individual candidates from the initial screen will be finally validated using single sgRNAs in combination with ICB therapy in appropriate colorectal cancer mouse models.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1479: Oncogene-driven immune escape (OncoEscape)
• Applicant Institution: Albert-Ludwigs-Universität Freiburg
• Project Head: Professor Dr. Florian R. Greten